LCT Parkinson’s trial resumes patient recruitment

Living Cell Technologies Limited today announced that it has received the necessary regulatory approval to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL®  in Parkinson’s disease. The trial was paused in December last year while the company completed internal and external audit and regulatory processes. 

Dr Ken Taylor, NTCELL Program Director and Acting Chief Executive, is pleased that patient recruitment in the clinical trial of NTCELL for Parkinson’s can resume. 

“This clinical trial is an initial step in progressing NTCELL to commercialisation as the first disease modifying treatment for Parkinson’s disease.” 

Existing treatments for Parkinson’s treat the symptoms rather than attempting to regenerate the affected brain cells. Many people with Parkinson’s no longer respond to these treatments. 

“LCT is committed to developing and marketing NTCELL for Parkinson’s patients not responding to current therapies. We also intend to further investigate the potential of our patented cell therapy as a treatment for other neurodegenerative disorders,” said Dr Taylor. 

Preclinical studies which confirmed NTCELL initiated nerve growth support the development of NTCELL as a potential treatment for other neurological diseases such as Huntington’s, Motor Neuron and Alzheimer’s. 

– Ends – 

For further information: www.lctglobal.com